全文获取类型
收费全文 | 1190篇 |
免费 | 85篇 |
国内免费 | 32篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 58篇 |
妇产科学 | 17篇 |
基础医学 | 108篇 |
口腔科学 | 31篇 |
临床医学 | 186篇 |
内科学 | 231篇 |
皮肤病学 | 12篇 |
神经病学 | 52篇 |
特种医学 | 246篇 |
外科学 | 181篇 |
综合类 | 26篇 |
预防医学 | 61篇 |
眼科学 | 8篇 |
药学 | 48篇 |
中国医学 | 5篇 |
肿瘤学 | 32篇 |
出版年
2023年 | 8篇 |
2021年 | 12篇 |
2020年 | 8篇 |
2019年 | 7篇 |
2018年 | 26篇 |
2017年 | 14篇 |
2016年 | 20篇 |
2015年 | 23篇 |
2014年 | 34篇 |
2013年 | 29篇 |
2012年 | 32篇 |
2011年 | 24篇 |
2010年 | 44篇 |
2009年 | 63篇 |
2008年 | 42篇 |
2007年 | 23篇 |
2006年 | 30篇 |
2005年 | 22篇 |
2004年 | 29篇 |
2003年 | 33篇 |
2002年 | 24篇 |
2001年 | 31篇 |
2000年 | 33篇 |
1999年 | 22篇 |
1998年 | 52篇 |
1997年 | 58篇 |
1996年 | 67篇 |
1995年 | 52篇 |
1994年 | 46篇 |
1993年 | 49篇 |
1992年 | 20篇 |
1991年 | 11篇 |
1990年 | 16篇 |
1989年 | 38篇 |
1988年 | 35篇 |
1987年 | 35篇 |
1986年 | 34篇 |
1985年 | 24篇 |
1984年 | 16篇 |
1983年 | 10篇 |
1982年 | 22篇 |
1981年 | 15篇 |
1980年 | 10篇 |
1979年 | 5篇 |
1978年 | 5篇 |
1977年 | 13篇 |
1976年 | 13篇 |
1975年 | 13篇 |
1971年 | 2篇 |
1965年 | 4篇 |
排序方式: 共有1307条查询结果,搜索用时 31 毫秒
1.
I Luyeye C Fievet J C Dupont C Durieux N Slimane J F Lecocq C Demarquilly J C Fruchart 《Clinical biochemistry》1988,21(4):255-261
Predefined monoclonal antibodies (Mabs) were used in an immunoenzymometric assay to study the immunochemical heterogeneity of lipoproteins and to search for potential epitopes with pathological importance. By measuring apolipoprotein B (apo B) epitopes in patients with and without angiographically documented coronary artery disease and in patients with type IIa hyperlipoproteinemia, we have found that both types of patients have a significant increase in Apo B-containing particles specifically recognized by one Mab (BL3). We have also observed that the effects of fenofibrate on type IIa patients vary greatly depending on the plasma concentrations of various Apo B-containing lipoproteins. The greatest effects occurred in patients with epitopes recognized by BL3. Lastly, by sequential precipitation of specific epitopes by BL3, we have obtained evidence that the residual epitope(s) may be related to one or more lipoprotein particles. 相似文献
2.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
3.
4.
5.
6.
7.
8.
9.
10.
The use of mixtures of well-defined monoclonal antibodies may represent a step forward in the standardization of immunochemical assays. We developed and optimized working conditions for using such a mixture to determine apolipoprotein A-I in human sera by two independent techniques (electroimmuno- and immunonephelometric-assays). Six monoclonal antibodies, each addressed to distinct epitopes located at the surface of apolipoprotein A-I, were used in combination to permit a reproducible measurement of the protein, without prior delipidation of samples. Parallel standard curves for a high-density lipoprotein subfraction (HDL3, the primary standard) and a reference serum (the secondary standard) were obtained. Within- and between-run coefficients of variation were acceptable for both methods. Apolipoprotein A-I concentrations, as measured in 60 subjects selected to present a large range of apolipoprotein content by electroimmunoassay (y1) and immunonephelometric assay (y2) with monoclonal antibodies, compared well with those measured by the same techniques but with polyclonal antibodies (x): r1 = 0.96, r2 = 0.99; y1 = 1.19x - 0.11 g/L, y2 = 0.98x. Comparison of results obtained by electroimmunoassay and immunonephelometric assay performed with monoclonal antibodies was also good: r = 0.96; y2 = 1.08y1 + 0.13 g/L. 相似文献